Bristol-Myers Squibb Completes Land Acquisition for New Biologics Facility

Friday, February 16, 2007 8:00 am EST

Dateline:

PRINCETON, N.J.

Public Company Information:

NYSE:
BMY

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) has completed the land purchase of an approximately 89-acre site from MassDevelopment for its new large-scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts. The company and MassDevelopment have also finalized agreements related to the facility's utility infrastructure, including waste water treatment and use of electricity, water and natural gas. Construction is expected to begin within the next several weeks, and the facility is projected to be operationally complete in 2009. The company plans to submit the site for regulatory approval in 2010.

The new Devens manufacturing facility is expected to support increased production capacity for commercially available biologic compounds, such as ORENCIA® (abatacept), and help meet future production needs of biologic compounds currently in development, including the company's investigational treatments for solid organ transplant rejection and certain types of cancers.

Bristol-Myers Squibb currently manufactures biologic compounds in a company-owned facility in Syracuse, NY, and finishes and packages biologic compounds in Manati, Puerto Rico. The company also has several partnerships with third-party manufacturers. These internal and external biologics resources remain important components of the company's overall strategy to expand its biologics portfolio.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 regarding plans to construct a biologics manufacturing facility that involves substantial risks and uncertainties. Specifically, there can be no guarantee that the construction of the facility will be completed or receive the regulatory approvals necessary to begin commercial production, or that such events will occur on the currently expected timelines. Nor is there any guaranty that the company's investigational biologic products whose production would be supported by the facility will be successfully developed or commercialized, or receive required regulatory approvals. A further list and description of risks and uncertainties can be found in the Bristol-Myers Squibb's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in its reports on Form 10-Q and Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Web site: http://www.bms.com/

Contact:

Media: Jeff Macdonald, Communications, +1-212-546-4824,
jeffrey.macdonald@bms.com, or Tony Plohoros, Communications, +1-609-252-7938,
tony.plohoros@bms.com, or Investors: John Elicker, Investor Relations,
+1-212-546-3775, john.elicker@bms.com, or Blaine Davis, Investor Relations,
+1-212-546-4631, blaine.davis@bms.com, all of Bristol-Myers Squibb Company

Privacy Policy
Business Wire NewsHQsm